Navigation Links
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
Date:1/15/2014

OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.

"I am delighted to welcome Tom at this transformative time for Oxford BioTherapeutics, as the company completes its transition into a fully-fledged oncology product development business," said Bryan Morton, Chairman of Oxford BioTherapeutics. "Dr Reynolds' experience in the oncology field will prove invaluable as we progress our pipeline into the clinic, and in particular his expertise in bringing antibody-drug conjugates to market having led the development and approval of ADCETRIS at Seattle Genetics."

Commenting on his appointment, Thomas C Reynolds MD, PhD, said, "I am highly impressed with Oxford BioTherapeutics' cancer targeting technology, which has continued to mature since my tenure at Seattle Genetics. I am delighted to be able to contribute to the development of the company's exciting antibody-based oncology products."

About Thomas C Reynolds MD, PhD

Dr Reynolds has held a number of senior development roles during his career of over 20 years in the biotechnology industry. Most recently he was Chief Medical Officer at Seattle Genetics, where he had direct oversight of the development and approval of the company's antibody-drug conjugate, ADCETRIS. Prior to this, he was Vice President for Medical Affairs at Zymogenetics, having held the role of Senior Medical Director. Previously, he held a number of senior roles at Targeted Genetics Corporation, culminating in the position of Vice President, Clinical Affairs. He began his industry career at Somatix Therapy Corporation as a Research Scientist. Dr Reynolds gained his MD at Stanford University, where he subsequently conducted postdoctoral research. He also holds a PhD in Biophysics from Stanford University, and a degree in Chemistry from Dartmouth College.

About Oxford BioTherapeutics

Oxford BioTherapeutics is developing a range of antibody-drug conjugates for cancer, based on its OGAP® oncology targeting technology. The OGAP® system incorporates one of the world's largest proprietary proteomic databases, with data on 7,500 cancer cell proteins providing unique, highly-qualified therapeutic targets. The company has established collaborations with leading antibody and cancer toxin technology companies, including Seattle Genetics, to build an in-house pipeline of antibody-drug conjugates (ADCs) against a number of these novel targets. In 2012, Oxford BioTherapeutics entered a strategic agreement to accelerate the development of its ADCs, with partner Menarini providing clinical and manufacturing expertise and investment of up to $1 billion in exchange for commercial rights to the treatments outside the US and Japan.

Oxford BioTherapeutics is based in Oxford, UK and San Jose, CA, and has a strong management team with significant experience of developing antibody-based therapies. The company has completed a number of funding rounds, and is supported by a syndicate of specialist venture capital investors. For more information please visit http://www.oxfordbiotherapeutics.com.

Contacts
Dr Christian Rohlff
CEO
Oxford BioTherapeutics
+44(0)1235-861770
christian.r@oxfordbiotherapeutics.com

David Dible / Sita Shah
Citigate Dewe Rogerson
+44(0)207-638-9571
david.d@citigatedr.co.uk


'/>"/>
SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford University Press to publish BioScience journal starting in 2014
2. Oxford BioMedica Announces Update from ARVO 2013
3. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
4. Oxford Performance Materials and Biomet Microfixation Join Forces
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Finance Completes $271.4 Million Securitization Transaction
7. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  Tempus, ... customized cancer care, and Penn,s Abramson Cancer Center ... have a positive response to immunotherapy treatment based ... As part of a research collaboration, ... pancreatic and melanoma cancer patient data to Penn. ...
(Date:11/30/2016)... 2016   Merck , a leading science and ... a set of agreements with Evotec AG, whereby Evotec ... genetic reagents such as CRISPR and shRNA libraries. Combining ... an accelerated pathway to explore and identify new drug ... of new targets, a process that can be time- ...
(Date:11/30/2016)... ... 2016 , ... On 28 November 2016, the International Union of Pure and ... moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, 115, 117, and ... the discoverers have been approved by the IUPAC Bureau. The IUPAC Council will be ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
Breaking Biology News(10 mins):